Bromfenac Ophthalmic
Bromfenac ophthalmic is a nonsteroidal anti-inflammatory (NSAID) eye drop used to treat inflammation and reduce eye pain after cataract surgery.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 19 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
📖 Bromfenac Ophthalmic: Patient Information Guide
A plain-language walkthrough of Bromfenac Ophthalmic — what it treats, how it works, how it’s taken, side effects, warnings and interactions. Tap any section to expand it.
What Bromfenac Ophthalmic is used for
▾
Bromfenac ophthalmic solution 0.07% is used after cataract surgery.
- Treats inflammation after cataract surgery
- Reduces eye pain after cataract surgery
How Bromfenac Ophthalmic works
▾
Bromfenac is an NSAID. It is thought to block the COX-1 and COX-2 enzymes that make prostaglandins. In animal studies, prostaglandins were shown to mediate certain kinds of inflammation inside the eye, so blocking them helps reduce inflammation and pain.
How Bromfenac Ophthalmic is taken (dosage)
▾
Bromfenac ophthalmic solution 0.07% is an eye drop used once a day in the affected eye.
- Start 1 day before cataract surgery.
- Continue on the day of surgery and through the first 14 days afterward.
- Wait at least 5 minutes between other eye drops.
- Keep the dropper tip clean and recap the bottle.
Follow your prescriber's directions and the label.
Bromfenac Ophthalmic side effects in detail
▾
The most common side effects, reported in 3% to 8% of patients in studies, were:
- Anterior chamber inflammation
- Foreign body sensation
- Eye pain
- Sensitivity to light
- Blurred vision
Contact your doctor promptly about worsening eye pain, vision changes, signs of corneal damage, unusual eye bleeding, or allergic or asthma-like symptoms.
Bromfenac Ophthalmic warnings and precautions
▾
- Corneal problems: keratitis, thinning, erosion, ulcers or perforation can occur and may threaten sight. Stop use if the corneal surface breaks down.
- Higher risk: complicated or repeat eye surgeries, corneal denervation or defects, diabetes, dry eye or other ocular surface disease, and rheumatoid arthritis.
- Duration: using it more than 24 hours before surgery or beyond 14 days afterward may raise corneal risk.
- Slow healing: especially when combined with topical steroids.
- Bleeding: may increase bleeding of eye tissues around surgery.
- Sulfite allergy: may cause allergic or asthmatic reactions in sensitive people.
- Cross-sensitivity: possible with aspirin and other NSAIDs.
Bromfenac Ophthalmic interactions: what it interacts with
▾
Check with your prescriber about these combinations.
- Topical steroid eye drops: together with NSAID drops, they may increase healing problems.
- Medicines that prolong bleeding: may add to bleeding risk.
- Other eye drops: can be used together, but space them at least 5 minutes apart.
- Soft contact lenses: may absorb the preservative, so remove them before dosing.
This is not a complete list of interactions. Always talk with your doctor or pharmacist before starting, stopping, or changing any medication.
Before taking Bromfenac Ophthalmic
▾
- There are no listed contraindications.
- Tell your doctor about sulfite, aspirin or NSAID sensitivity, or asthma.
- Tell your doctor about bleeding problems, diabetes, rheumatoid arthritis, dry eye or past corneal problems.
- Avoid in late pregnancy.
- Breastfeeding: discuss benefits and risks with your doctor.
- Not established in children.
- No overall differences seen in adults 70 and older.
Pharmacodynamics: what Bromfenac Ophthalmic does in the body
▾
Bromfenac reduces prostaglandin production by inhibiting COX-1 and COX-2. In animal eyes, prostaglandins have been shown to disrupt the blood-aqueous humor barrier, widen blood vessels, increase vessel leakiness and raise eye pressure.
Pharmacokinetics: how your body processes Bromfenac Ophthalmic
▾
The blood level of bromfenac after Prolensa eye drops in humans is unknown. Based on the maximum dose, the level in the blood is estimated to be below what can be measured. Exposure to the rest of the body is expected to be low.
How to store Bromfenac Ophthalmic
▾
Store at 20º - 25ºC (68º - 77ºF) .
📄 Written from Bromfenac Ophthalmic’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Every point is grounded in that labeling — nothing is invented. How we use AI →
Supplements & herbs that interact with Bromfenac Ophthalmic
209 supplements and herbal products have documented interactions with Bromfenac Ophthalmic in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.
- Major · 4
- Moderate · 186
- Minor · 19
Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
Nutrient depletion considerations
Bromfenac Ophthalmic has been associated with lower levels of 1 nutrient in the clinical literature. This does not mean a deficiency will occur — it means these may be worth discussing with your pharmacist or healthcare provider, especially with long-term use.
Educational information from a licensed clinical database (Natural Medicines) — not medical advice. Do not start or stop medications or supplements without professional guidance.
🩺 Bromfenac Ophthalmic: pharmacist answers to common questions
Quick, plain-English answers to the questions patients ask most about Bromfenac Ophthalmic — the kind of thing our pharmacy team would talk through with you at the counter.
What is this eye drop for?
▾
How long do I use it?
▾
Can I wear my contacts or use other drops?
▾
What side effects should I expect?
▾
Is it safe if I'm pregnant or breastfeeding?
▾
Who should be extra careful with it?
▾
Is Bromfenac Ophthalmic available over the counter?
▾
When was Bromfenac Ophthalmic first available?
▾
Who makes Bromfenac Ophthalmic?
▾
💬 Answers drafted from Bromfenac Ophthalmic’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Grounded in that labeling — nothing is made up. How we use AI →
🧰 More about Bromfenac Ophthalmic on HelloPharmacist
💊 Bromfenac Ophthalmic forms and strengths (how it comes)
Bromfenac Ophthalmic is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Eye drops
How this form is used
- Bromfenac ophthalmic solution 0.07% is used to treat inflammation and reduce eye pain after cataract surgery.
- Bromfenac ophthalmic solution 0.07% is given as one drop in the affected eye once daily, starting 1 day before surgery and continuing through the first 14 days after surgery.
- Bromfenac ophthalmic solution 0.07%: remove contact lenses first and wait at least 10 minutes before putting them back in.
- Bromfenac ophthalmic solution 0.07%: wait at least 5 minutes between this and other eye drops.
📊 Bromfenac Ophthalmic on the U.S. market: products, makers and brands
How Bromfenac Ophthalmic appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
📈 How widely Bromfenac Ophthalmic is used (Medicaid data)
A general measure of how commonly Bromfenac Ophthalmic is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Bromfenac Ophthalmic is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Bromfenac Ophthalmic prescribed? Of the 1,599 medications we measure, Bromfenac Ophthalmic ranks #1,106 by Medicaid prescriptions — more than 31% of them.
Utilization by Bromfenac Ophthalmic product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
bromfenac 0.7 MG/ML Ophthalmic Solution Most dispensed
Summed across the 6 of 11 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1375917
bromfenac 0.9 MG/ML Ophthalmic Solution
Summed across the 3 of 9 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 578018
bromfenac 0.75 MG/ML Ophthalmic Solution
Summed across the 1 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1790141
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Bromfenac Ophthalmic, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 10 of 23 listed Bromfenac Ophthalmic NDCs with Medicaid activity.
🔍 Compare Bromfenac Ophthalmic products
A representative set of FDA-listed product records for Bromfenac Ophthalmic — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Eye drops | ||||
| 1.035 mg/mL | Ophthalmic | Akorn | ANDA | View NDC → |
| 0.805 mg/mL | Ophthalmic | Alembic Pharmaceuticals Inc. | ANDA | View NDC → |
| 1.035 mg/mL | Ophthalmic | Alembic Pharmaceuticals Inc. × 3 listings | ANDA | View NDC → |
| 0.805 mg/mL | Ophthalmic | Alembic Pharmaceuticals Limited | ANDA | View NDC → |
| 1.035 mg/mL | Ophthalmic | Alembic Pharmaceuticals Limited | ANDA | View NDC → |
| 0.7 mg/mL | Ophthalmic | Amneal Pharmaceuticals NY LLC | ANDA | View NDC → |
| 0.7 mg/mL | Ophthalmic | Apotex Corp. | ANDA | View NDC → |
| 1.035 mg/mL | Ophthalmic | Armas Pharmaceuticals Inc. | ANDA | View NDC → |
| 0.9 mg/mL | Ophthalmic | Aurobindo Pharma Limited × 2 listings | ANDA | View NDC → |
| 0.7 mg/mL | Ophthalmic | Bausch & Lomb Americas Inc. × 2 listings | NDA AUTHORIZED GENERIC | View NDC → |
| 0.7 mg/mL | Ophthalmic | Bausch & Lomb Incorporated × 3 listings | NDA | View NDC → |
| 0.7 mg/mL | Ophthalmic | Dr. Reddy's Laboratories Inc. | NDA AUTHORIZED GENERIC | View NDC → |
| 0.9 mg/mL | Ophthalmic | Fosun Pharma USA Inc. × 2 listings | ANDA | View NDC → |
| 0.9 mg/mL | Ophthalmic | Gland Pharma Limited | ANDA | View NDC → |
| 0.75 mg/mL | Ophthalmic | Lupin Pharmaceuticals, Inc. | ANDA | View NDC → |
| 0.805 mg/mL | Ophthalmic | Lupin Pharmaceuticals, Inc. × 2 listings | ANDA | View NDC → |
| 0.9 mg/mL | Ophthalmic | Lupin Pharmaceuticals, Inc. × 2 listings | ANDA | View NDC → |
| 0.76 mg/mL | Ophthalmic | Sun Pharmaceutical Industries, Inc. | NDA AUTHORIZED GENERIC | View NDC → |
| 0.76 mg/mL | Ophthalmic | Sun Pharmaceutical Industries, Inc. × 3 listings | NDA | View NDC → |
Showing 30 of 30 products — FDA National Drug Code Directory. See every product, package size and price: browse all 30 Bromfenac Ophthalmic NDCs →
📈 Bromfenac Ophthalmic side effects reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Bromfenac Ophthalmic — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Bromfenac Ophthalmic in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
🏛️ Bromfenac Ophthalmic FDA approval history
How Bromfenac Ophthalmic went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
🚨 Bromfenac Ophthalmic recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
Source: openFDA drug enforcement (recall) reports.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 19737 1 dose form · 3 strengths
-
Dose form (SCDF) Ophthalmic Solution RxCUI 578017In current FDA listingsClinical drug / strength (SCD) 0.7 MG/MLRxCUI 13759170.75 MG/MLRxCUI 17901410.9 MG/MLRxCUI 578018
Look up RxCUI 19737 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
📦 Bromfenac Ophthalmic supply and shortage status
Whether Bromfenac Ophthalmic is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
🏷️ Bromfenac Ophthalmic brand names
🏭 Who makes Bromfenac Ophthalmic: manufacturers and labelers
Bromfenac Ophthalmic drug class (RxNorm)
Bromfenac Ophthalmic belongs to the Nonsteroidal Anti-inflammatory Drug class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
🔬 Sources for this Bromfenac Ophthalmic page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How we combine label and product data
HelloPharmacist combines public FDA and NLM records; we don’t author the underlying clinical facts. We identified 19 FDA-filed SPL label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. The representative label is the starting point for the displayed reference monograph; the 12 largest stored in-scope SPL records, which may include that representative, are compared section by section, and the longest available version of each section is retained. Forms, routes, brands, labelers, product-listed strengths, and product-record counts are aggregated separately from ingredient-matched FDA NDC Directory records; package records listed above are associated with the linked SPL; and the normalized concept hierarchy comes from NLM RxNorm.
Where a section is identified as AI-written, its plain-language text is generated from bounded label evidence. New draft drug pages remain in the admin review queue before first publication. Bausch & Lomb Americas Inc. is the representative DailyMed label linked for verification and dates; it is not the sole source used for the page.
This is general education, not medical advice — always consult your doctor or pharmacist about your medications and any medical condition. For the exact wording of the linked representative label, view that label on DailyMed; some displayed composite sections may come from other in-scope SPL labels. Learn how we use AI and our data sources & update cadence.